Leerink Partnrs Has Bearish Estimate for ABT FY2025 Earnings

Abbott Laboratories (NYSE:ABT - Free Report) - Investment analysts at Leerink Partnrs dropped their FY2025 earnings per share (EPS) estimates for shares of Abbott Laboratories in a report issued on Friday, July 18th. Leerink Partnrs analyst M. Kratky now expects that the healthcare product maker will earn $5.14 per share for the year, down from their previous forecast of $5.15. Leerink Partnrs currently has a "Hold" rating on the stock. The consensus estimate for Abbott Laboratories' current full-year earnings is $5.14 per share. Leerink Partnrs also issued estimates for Abbott Laboratories' Q4 2025 earnings at $1.47 EPS, Q1 2026 earnings at $1.23 EPS, Q2 2026 earnings at $1.39 EPS, Q3 2026 earnings at $1.43 EPS, Q4 2026 earnings at $1.61 EPS, FY2026 earnings at $5.67 EPS, FY2027 earnings at $6.25 EPS, FY2028 earnings at $6.87 EPS and FY2029 earnings at $7.54 EPS.

Other equities research analysts also recently issued research reports about the stock. Morgan Stanley boosted their price objective on shares of Abbott Laboratories from $127.00 to $137.00 and gave the company an "equal weight" rating in a research report on Tuesday, July 15th. BTIG Research lowered their target price on Abbott Laboratories from $148.00 to $145.00 and set a "buy" rating on the stock in a research report on Friday. Royal Bank Of Canada upped their price target on Abbott Laboratories from $145.00 to $147.00 and gave the stock an "outperform" rating in a research report on Tuesday, July 15th. William Blair raised Abbott Laboratories to a "strong-buy" rating in a research report on Thursday. Finally, Evercore ISI increased their target price on shares of Abbott Laboratories from $140.00 to $145.00 and gave the stock an "outperform" rating in a report on Tuesday, July 8th. Five investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $144.47.

Abbott Laboratories Stock Up 2.7%

Shares of ABT stock opened at $123.81 on Monday. The company has a current ratio of 1.78, a quick ratio of 1.27 and a debt-to-equity ratio of 0.26. Abbott Laboratories has a 12 month low of $99.92 and a 12 month high of $141.23. The stock has a market cap of $215.41 billion, a P/E ratio of 15.52, a P/E/G ratio of 2.35 and a beta of 0.73. The company has a 50 day simple moving average of $132.98 and a two-hundred day simple moving average of $129.68.

Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.26. The business had revenue of $11.14 billion for the quarter, compared to analysts' expectations of $11.01 billion. Abbott Laboratories had a return on equity of 18.83% and a net margin of 32.43%. The business's revenue for the quarter was up 7.4% on a year-over-year basis. During the same period last year, the firm posted $1.14 earnings per share.

Abbott Laboratories Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, August 15th. Shareholders of record on Tuesday, July 15th will be paid a $0.59 dividend. This represents a $2.36 annualized dividend and a yield of 1.91%. The ex-dividend date of this dividend is Tuesday, July 15th. Abbott Laboratories's payout ratio is currently 29.57%.

Insider Activity at Abbott Laboratories

In other news, Director Sally E. Blount sold 2,600 shares of Abbott Laboratories stock in a transaction dated Wednesday, April 30th. The stock was sold at an average price of $129.66, for a total value of $337,116.00. Following the sale, the director directly owned 34,058 shares of the company's stock, valued at approximately $4,415,960.28. The trade was a 7.09% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.46% of the stock is owned by company insiders.

Hedge Funds Weigh In On Abbott Laboratories

Institutional investors have recently added to or reduced their stakes in the company. Hughes Financial Services LLC purchased a new position in shares of Abbott Laboratories in the first quarter valued at $27,000. Abound Financial LLC bought a new position in Abbott Laboratories during the first quarter valued at $28,000. Redwood Park Advisors LLC bought a new position in Abbott Laboratories during the fourth quarter valued at $25,000. Elequin Capital LP purchased a new position in shares of Abbott Laboratories in the 1st quarter worth $30,000. Finally, JCIC Asset Management Inc. bought a new stake in shares of Abbott Laboratories in the 1st quarter worth about $32,000. Hedge funds and other institutional investors own 75.18% of the company's stock.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.